ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its lead product candidates are loncastuximab tesirine (ADCT-402), an ADC that is in a Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, and Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL, as well as Phase I/II clinical trial in combination with ibrutinib for relapsed or refractory DLBCL and mantle cell lymphoma; and camidanlumab tesirine (ADCT-301), an ADC that is in a pivotal Phase II clinical trial for the treatment of relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma, and Phase Ib clinical trial for selected advanced solid tumors. The company also develops clinical-stage product candidates, such as ADCT-601 that is in a Phase Ia clinical trial for the treatment of selected advanced tumors; and ADCT-602, and a Phase I/II clinical trial for relapsed or refractory acute lymphoblastic leukemia, as well as preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of selected advanced solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, and Synaffix B.V. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
IPO Year: 2020
Exchange: NYSE
Website: adctherapeutics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/8/2024 | $6.00 | Overweight | Stephens |
| 5/30/2024 | Overweight | Cantor Fitzgerald | |
| 3/28/2024 | $11.00 | Buy | Guggenheim |
| 8/10/2023 | Underweight → Neutral | JP Morgan | |
| 4/24/2023 | $7.00 → $2.00 | Neutral → Underperform | BofA Securities |
| 12/6/2022 | $12.00 | Overweight | CapitalOne |
| 11/9/2022 | $14.00 → $7.00 | Buy → Neutral | BofA Securities |
| 9/21/2022 | $5.00 | Overweight | JP Morgan |
| 9/9/2022 | $17.00 → $11.00 | Overweight → Equal-Weight | Morgan Stanley |
| 3/4/2022 | $55.00 → $54.00 | Buy | HC Wainwright & Co. |
4 - ADC Therapeutics SA (0001771910) (Issuer)
4 - ADC Therapeutics SA (0001771910) (Issuer)
4 - ADC Therapeutics SA (0001771910) (Issuer)
4 - ADC Therapeutics SA (0001771910) (Issuer)
4 - ADC Therapeutics SA (0001771910) (Issuer)
4 - ADC Therapeutics SA (0001771910) (Issuer)
4 - ADC Therapeutics SA (0001771910) (Issuer)
4 - ADC Therapeutics SA (0001771910) (Issuer)
4 - ADC Therapeutics SA (0001771910) (Issuer)
4 - ADC Therapeutics SA (0001771910) (Issuer)
LAUSANNE, Switzerland, April 1, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 128,600 of the Company's common shares to two new employees on April 1, 2025 (each, a "Grant"). The Grants were offered as material inducement to the employees' employment. The grants were approved by the Compensation Committee of the Company's Board of Directors pursuant to the Company's Inducement Plan to motiva
LAUSANNE, Switzerland, April 1, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT) announced today that Ameet Mallik, Chief Executive Officer, will present a company overview at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025, at 8:00 a.m. ET. A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics' website, ir.adctherapeutics.com. A replay of the webcast will be available for approximately 30 days. About ADC Therapeutics ADC Therapeutics (NYSE:ADCT) is a commercial-
Initial data from LOTIS-7 Phase 1b trial of ZYNLONTA® plus glofitamab demonstrated clinically meaningful benefit with 94% best ORR and 72% CR rate; data update expected in second quarter 2025 Completed enrollment in LOTIS-5 Phase 3 confirmatory trial of ZYNLONTA plus rituximab in patients with 2L+ DLBCL; data update anticipated in late 2025 once PFS events reached $250.9M in cash as of December 31, 2024, provides runway expected to fund operations into the second half of 2026 Company to host conference call today at 8:30 a.m. EDT LAUSANNE, Switzerland, March 27, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug c
Oral presentation to highlight preclinical investigation of Claudin-6 ADC in ovarian and NSCLC cancer models Preclinical data for PSMA and ASCT2-targeted ADCs accepted for poster presentations LAUSANNE, Switzerland, March 25, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced abstracts detailing multiple preclinical programs have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30, 2025, in Chicago, Illinois.
LAUSANNE, Switzerland, March 20, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Thursday, March 27, 2025, at 8:30 a.m. EDT to report financial results for the fourth quarter and year ended December 31, 2024, and provide operational updates. To access the conference call, please register here. The participant toll-free dial-in number is 1-800-836-8184 for North America and Canada. It is recommended that you
LAUSANNE, Switzerland, Feb. 3, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 26,800 of the Company's common shares to three new employees on February 3, 2025 (each, a "Grant"). The Grants were offered as material inducement to the employees' employment. The grants were approved by the Compensation Committee of the Company's Board of Directors pursuant to the Company's Inducement Plan to mot
LAUSANNE, Switzerland, Jan. 30, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on Thursday, February 6, 2025, at 2:00 p.m. ET. A live webcast of the presentation will be available via the Events & Presentations page in the IR section of the ADC Therapeutics website. A replay of the webcast will be available for approximately 30 days. Abou
LAUSANNE, Switzerland, Jan. 2, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 20,000 of the Company's common shares to two new employees on January 2, 2025 (each, a "Grant"). The Grants were offered as material inducement to the employees' employment. The grants were approved by the Compensation Committee of the Company's Board of Directors pursuant to the Company's Inducement Plan to motiva
LAUSANNE, Switzerland, Dec. 30, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced the completion of enrollment in LOTIS-5, the Phase 3 confirmatory trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with rituximab (Lonca-R) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). ZYNLONTA previously received accelerated approval for the treatment of r/r DLBCL after two or more lines of systemic therapy from the FDA in 2021.
ZYNLONTA in combination with glofitamab demonstrated clinically meaningful benefit with 94% best ORR and 72% CR rate Safety data show no dose-limiting toxicities (DLTs), no high-grade cytokine release syndrome (CRS) or high-grade immune effector cell-associated neurotoxicity syndrome (ICANS) across all patients Company to host conference call today at 8:30 a.m. EST LAUSANNE, Switzerland, Dec. 11, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced positive initial data from the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA® in combination
Stephens initiated coverage of ADC Therapeutics with a rating of Overweight and set a new price target of $6.00
Cantor Fitzgerald initiated coverage of ADC Therapeutics with a rating of Overweight
Guggenheim initiated coverage of ADC Therapeutics with a rating of Buy and set a new price target of $11.00
JP Morgan upgraded ADC Therapeutics from Underweight to Neutral
BofA Securities downgraded ADC Therapeutics from Neutral to Underperform and set a new price target of $2.00 from $7.00 previously
CapitalOne initiated coverage of ADC Therapeutics with a rating of Overweight and set a new price target of $12.00
BofA Securities downgraded ADC Therapeutics from Buy to Neutral and set a new price target of $7.00 from $14.00 previously
JP Morgan initiated coverage of ADC Therapeutics with a rating of Overweight and set a new price target of $5.00
Morgan Stanley downgraded ADC Therapeutics from Overweight to Equal-Weight and set a new price target of $11.00 from $17.00 previously
HC Wainwright & Co. reiterated coverage of ADC Therapeutics with a rating of Buy and set a new price target of $54.00 from $55.00 previously
Initial data from LOTIS-7 Phase 1b trial of ZYNLONTA® plus glofitamab demonstrated clinically meaningful benefit with 94% best ORR and 72% CR rate; data update expected in second quarter 2025 Completed enrollment in LOTIS-5 Phase 3 confirmatory trial of ZYNLONTA plus rituximab in patients with 2L+ DLBCL; data update anticipated in late 2025 once PFS events reached $250.9M in cash as of December 31, 2024, provides runway expected to fund operations into the second half of 2026 Company to host conference call today at 8:30 a.m. EDT LAUSANNE, Switzerland, March 27, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug c
LAUSANNE, Switzerland, March 20, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Thursday, March 27, 2025, at 8:30 a.m. EDT to report financial results for the fourth quarter and year ended December 31, 2024, and provide operational updates. To access the conference call, please register here. The participant toll-free dial-in number is 1-800-836-8184 for North America and Canada. It is recommended that you
ZYNLONTA in combination with glofitamab demonstrated clinically meaningful benefit with 94% best ORR and 72% CR rate Safety data show no dose-limiting toxicities (DLTs), no high-grade cytokine release syndrome (CRS) or high-grade immune effector cell-associated neurotoxicity syndrome (ICANS) across all patients Company to host conference call today at 8:30 a.m. EST LAUSANNE, Switzerland, Dec. 11, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced positive initial data from the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA® in combination
Company to host corporate update webcast to share results on December 11, 2024 LAUSANNE, Switzerland, Dec. 6, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), today announced that it will host a conference call and live webcast on Wednesday, December 11, 2024, at 8:30 a.m. EST to provide an update on preliminary data from the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA® in combination with the bispecific antibody glofitamab (COLUMVI™) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). To access
LOTIS-5 full enrollment and LOTIS-7 initial efficacy, safety update anticipated by end of 2024 Updated ZYNLONTA® Phase 2 IIT data in indolent lymphomas to be presented at the 66th American Society of Hematology Annual Meeting in December 2024 Discontinuing ADCT-601 program and prioritizing exatecan-based platform for solid tumors Company to host conference call today at 8:30 a.m. EST LAUSANNE, Switzerland, Nov. 7, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results for the third quarter ended September 30, 2024, and provided recent operational updates.
LAUSANNE, Switzerland, Oct. 31, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Thursday, November 7, 2024, at 8:30 a.m. EST to report financial results for the third quarter 2024 and provide operational updates. To access the conference call, please register here. The participant toll-free dial-in number is 1-800-836-8184 for North America and Canada. It is recommended that you join 10 minutes before the ev
ZYNLONTA® net sales of $17.0 million in 2Q 2024; Commercial profitability achieved during first half of 2024 LOTIS-7 trial enrollment on track with efficacy and safety data on eligible patients expected by year-end 2024 and mature data on all patients expected in first half of 2025 Full enrollment in LOTIS-5 trial expected before year-end 2024 Company to host conference call today at 8:30 a.m. EDT LAUSANNE, Switzerland, Aug. 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results for the second quarter ended June 30, 2024, and provided operational updates
LAUSANNE, Switzerland, July 30, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Tuesday, August 6, 2024, at 8:30 a.m. EDT to report financial results for the second quarter 2024 and provide operational updates. To access the conference call, please register here. Registrants will receive the dial-in number and unique PIN. It is recommended that you join 10 minutes before the event, though you may pre-register at any time. A live webcast of the call will be available under "Events and Presentations" in the Inve
ZYNLONTA® (loncastuximab tesirine-lpyl) net sales of $17.8 million in 1Q 2024; total operating expenses decreased 25% (adjusted total operating expenses decreased 16%)1 compared to 1Q 2023 Successfully completed LOTIS-7 dose escalation and initiated expansion in 2L+ DLBCL Initial MZL IIT Phase 2 data from 15 patients showed 13 patients with CR and 1 patient with PR; encouraging data compared to current treatments in area with high unmet medical need Research event featured next-generation ADC platform and the Company's most advanced ADC targets including promising preclinical data in NaPi2b, Claudin-6, PSMA and ASCT2 Company to host conference call today at 8:30 a.m. EDT LAUSA
LAUSANNE, Switzerland, May 01, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE:ADCT) today announced that it will host a conference call and live webcast on Monday, May 6, 2024 at 8:30 a.m. EDT to report financial results for the first quarter 2024 and provide updates on recent progress against key catalysts from the pipeline. To access the conference call, please register here. Registrants will receive the dial-in number and unique PIN. It is recommended that you join 10 minutes before the event, though you may pre-register at any time. A live webcast of the call will be available under "Events and Presentations" in the Investors section of the ADC Therapeutics website at ir.adctherap
Submission status for ADC Therapeutics SA's drug ZYNLONTA (SUPPL-5) with active ingredient LONCASTUXIMAB TESIRINE-LPYL has changed to 'Approval' on 10/12/2022. Application Category: BLA, Application Number: 761196, Application Classification:
Submission status for ADC Therapeutics SA's drug ZYNLONTA (SUPPL-4) with active ingredient LONCASTUXIMAB TESIRINE-LPYL has changed to 'Approval' on 10/12/2022. Application Category: BLA, Application Number: 761196, Application Classification:
Submission status for ADC Therapeutics SA's drug ZYNLONTA (ORIG-1) with active ingredient LONCASTUXIMAB TESIRINE-LPYL has changed to 'Approval' on 04/23/2021. Application Category: BLA, Application Number: 761196, Application Classification:
SC 13G/A - ADC Therapeutics SA (0001771910) (Subject)
SC 13G/A - ADC Therapeutics SA (0001771910) (Subject)
SC 13G/A - ADC Therapeutics SA (0001771910) (Subject)
SC 13G - ADC Therapeutics SA (0001771910) (Subject)
SC 13D/A - ADC Therapeutics SA (0001771910) (Subject)
SC 13G/A - ADC Therapeutics SA (0001771910) (Subject)
SC 13G/A - ADC Therapeutics SA (0001771910) (Subject)
SC 13G/A - ADC Therapeutics SA (0001771910) (Subject)
SC 13D/A - ADC Therapeutics SA (0001771910) (Subject)
SC 13G - ADC Therapeutics SA (0001771910) (Subject)
DEF 14A - ADC Therapeutics SA (0001771910) (Filer)
DEFA14A - ADC Therapeutics SA (0001771910) (Filer)
PRE 14A - ADC Therapeutics SA (0001771910) (Filer)
10-K - ADC Therapeutics SA (0001771910) (Filer)
8-K - ADC Therapeutics SA (0001771910) (Filer)
SCHEDULE 13G - ADC Therapeutics SA (0001771910) (Subject)
8-K - ADC Therapeutics SA (0001771910) (Filer)
8-K - ADC Therapeutics SA (0001771910) (Filer)
10-Q - ADC Therapeutics SA (0001771910) (Filer)
8-K - ADC Therapeutics SA (0001771910) (Filer)
4 - ADC Therapeutics SA (0001771910) (Issuer)
4 - ADC Therapeutics SA (0001771910) (Issuer)
£90m ($114m) series A co-led by new leading life science investors Novo Holdings and AbingworthAdditional new investors British Patient Capital, Cancer Research Horizons and Lilly participated alongside founding investors Brandon Capital and Sofinnova PartnersFunds will be used to build out Myricx Bio's proprietary N-Myristoyltransferase inhibitor (NMTi) antibody-drug conjugate (ADC) payload platform and advance its pipeline of NMTi-ADCs through clinical proof of concept targeting clinically validated tumour-associated antigensCompany to establish laboratory operations in London's biotech hub, and expand its management and R&D teamsMichael Bauer from Novo Holdings and Lucille Conroy from Abi
LAUSANNE, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE:ADCT) today announced that the Company is set to join the Russell 2000® Index and the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024. "We are pleased to be joining the Russell 2000® Index," said Ameet Mallik, Chief Executive Officer of ADC Therapeutics. "This is a significant benchmark validating the focused execution of our corporate and capital allocation strategy and our progress toward multiple upcoming expected milestones throughout our hematology and solid tumor portfolios." Th
LONDON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx'), a UK biotech company focused on the discovery and development of a completely novel class of antibody-drug conjugate (ADC) payloads based on N-Myristoyltransferase inhibition (NMTi), today announces the appointment of Dr Chris Martin as independent Chairman to its Board of Directors. Dr Martin is a renowned biotech company founder, director and entrepreneur, and a pioneer and leader in the ADC space. Dr Martin was instrumental in co-founding ADC Therapeutics (NYSE:ADCT) in Jan 2012 and served as its CEO since inception until May 2022. Under his leadership, ADC Therapeutics grew from a private biotech start-up to a New York
LONDON, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx'), a UK biotech company focusing on the discovery and development of a completely novel class of selectively cytotoxic payloads for antibody-drug conjugates (ADCs), today announces the appointment of Francesca Zammarchi, Ph.D., as Chief Scientific Officer (CSO). Dr. Zammarchi joins Myricx as it accelerates the development of its pipeline of ADCs based on its first-in-class N-myristoyltransferase inhibitor (NMTi) payload platform. She brings over two decades of cancer biology research experience, including developing ADCs, gained working in the biopharma industry and in academia. At Myricx, as a senior member of the Leadership T
Strengthens the Board with the election of Robert W. Azelby as director Board will be comprised of nine directors; gratitude expressed for contributions of outgoing directors LAUSANNE, Switzerland, June 15, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE:ADCT) today announced the election of Robert W. Azelby to its Board of Directors. Mr. Azelby brings more than 30 years of biopharmaceutical leadership and commercial experience to ADC Therapeutics' Board. "We're delighted to welcome Bob to our Board. He brings with him a wealth of experience and a strong track record in building successful biotech companies. This expertise will be invaluable at this time as we execu
ADC Therapeutics SA (NYSE:ADCT) today announced the appointment of industry veteran Mohamed Zaki, MD, PhD, as Chief Medical Officer (CMO), effective January 3, 2023. He will serve on the Company's executive leadership team. Dr. Zaki succeeds Joseph Camardo, MD, who is stepping down from full-time work to pursue other avenues to engage with the pharmaceutical industry and patient community. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230103005766/en/Mohamed Zaki, MD, PhD, Chief Medical Officer, ADC Therapeutics (Photo: Business Wire) "We are excited to welcome Dr. Zaki to ADC Therapeutics and look forward to his leadership of t
ADC Therapeutics SA (NYSE:ADCT) today announced the appointment of Jose "Pepe" Carmona as Chief Financial Officer (CFO), effective December 19, 2022. He will serve on the Company's executive leadership team and succeeds Jenn Creel, who is leaving to pursue other opportunities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221219005210/en/Jose Carmona, Chief Financial Officer, ADC Therapeutics (Photo: Business Wire) "We warmly welcome Pepe to ADC Therapeutics. As we enter the next phase of growth, I am confident that his extensive financial background, deep capital markets experience and proven leadership in the pharmaceutical in
ADC Therapeutics SA (NYSE:ADCT) today announced the appointment of Kristen Harrington-Smith as Chief Commercial Officer, effective November 17, 2022. The Company also announced the appointment of Peter Graham as Chief Legal Officer, effective November 1, 2022. Both Ms. Harrington-Smith and Mr. Graham will serve on the Company's leadership team. Kristen Harrington-Smith appointed as Chief Commercial Officer "We are delighted to welcome Kristen to ADC Therapeutics. She has an extraordinary commercial background in the DLBCL landscape having led the commercial teams for serious hematological diseases, including major launches of innovative cell therapy products. We have complete conviction t
Ameet Mallik, Chief Executive Officer of ADC Therapeutics, also joins the Board ADC Therapeutics SA (NYSE:ADCT) today announced the appointment of veteran oncology drug developer Jean-Pierre Bizzari, MD, to its Board of Directors. Additionally, Ameet Mallik, who was appointed as the Company's Chief Executive Officer in May 2022, will join the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220701005047/en/Jean-Pierre Bizzari, MD (Photo: Business Wire) "Jean-Pierre is an exceptional addition to our Board," said Ron Squarer, Chairman of ADC Therapeutics' Board of Directors. "His integral role in the development and approval
Co-Founder Chris Martin transitions CEO role to industry veteran Ameet Mallik Dr. Martin to serve on Board of Directors and as Chair of the Science and Technology Committee ADC Therapeutics SA (NYSE:ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, announced that Chris Martin, DPhil, has stepped down as Chief Executive Officer. Dr. Martin will serve as a non-executive member of the Company's Board of Directors and Chair of the Science and Technology Committee. He will also serve as an advisor to the Company for the ne